Search | Clinical Trials Finder

Conditions: Psoriasis
Interventions: RA-18C3; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Owensboro, Kentucky • Ann Arbor, Michigan • Austin, Texas

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine; Drug · Biological
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 39
States / cities: Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: End-Stage Renal Disease, Kidney Transplantation
Interventions: Intravenous immune globulin (IVIG); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety), SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety), IV treatment with IGSC, 10%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 2 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: Cypress, California • Irvine, California • Los Angeles, California + 8 more

Conditions: Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
Interventions: Canakinumab (ACZ885); Drug
Lead sponsor: Novartis; Industry
Eligibility: 3 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more

Conditions: Systemic Sclerosis
Interventions: Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Middle East Respiratory Syndrome Coronavirus
Interventions: SAB-301, Normal (9%) Saline; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV
Interventions: PRO 140; Biological
Lead sponsor: Drexel University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Stanford, California • Denver, Colorado • St Louis, Missouri + 3 more

Conditions: Myasthenia Gravis
Interventions: HIZENTRA ®; Drug
Lead sponsor: Mazen Dimachkie, MD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Phoenix, Arizona • Kansas City, Kansas • Buffalo, New York + 1 more

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more

Conditions: Neoplasms
Interventions: Ami-LC-MD, Ami-LC, Ami-HC, Ami-HC-CF; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: West Hollywood, California • Indianapolis, Indiana • New York, New York + 2 more

Conditions: Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions: Intravenous immunoglobulin, 0.9% Sodium Chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more

Conditions: Rabies, Rabies Human, Rabies Virus Infection, Pediatrics
Interventions: Human rabies immune globulin 300 IU/mL; Biological
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: Up to 17 Years
Enrollment: 35 participants
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: HYQVIA; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 19 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Systemic Lupus Erythematosus
Interventions: Belimumab 100 mg SC; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 10
States / cities: Birmingham, Alabama • Long Beach, California • Tampa, Florida + 7 more

Conditions: Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy
Interventions: Intravenously administered pooled human immunoglobulin (IVIG); Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Pittsburgh, Pennsylvania + 2 more

Conditions: Rheumatoid Arthritis
Interventions: Natrunix, Placebo; Drug
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 26
States / cities: Covina, California • Encino, California • Rancho Mirage, California + 19 more

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Immune Globulin Intravenous (Human), 10%; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 24 Months and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 6 more

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Interventions: Humanized anti-Factor Bb monoclonal antibody, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Obesity, Obese, Overweight or Obesity
Interventions: Bimagrumab, Semaglutide, Placebo; Biological · Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more

Conditions: Rabies
Interventions: Active rabies vaccine (US-FDA approved); Drug
Lead sponsor: Kamada, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions: Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide, Fludarabine, G-CSF, Melphalan, Mesna, Rituximab, Tacrolimus, Thiotepa, HPC,A Infusion, CliniMACS, Sirolimus; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Indolent Systemic Mastocytosis
Interventions: sarilumab, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

PRO 140 for Human Immunodeficiency Virus Infection

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

Phase 3 IGIV, 10% in Alzheimer´s Disease

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Survey of Human Rabies Immune Globulin Safety in Children

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis